Claims for Patent: 5,874,414

Summary for Patent: 5,874,414

Title:	Trans-splicing ribozymes
Abstract:	The design of new ribozymes capable of self-catalyzed trans-splicing which are based upon the catalytic core of a Group I intron are described. Using this design, it is possible to construct ribozymes capable of efficiently splicing a new 3\' exon sequence into any chosen target RNA sequence in a highly precise manner. Inactive pro-ribozyme forms are also described.
Inventor(s):	Haseloff; James (Cambridge, MA), Goodman; Howard M. (Newtown, MA)
Assignee:	The General Hospital Corporation (Boston, MA)
Application Number:	08/090,192
Patent Claims:	1. A group I type intron polynucleotide molecule, said polynucleotide molecule comprising a sequence encoding a trans-splicing ribozyme, said ribozyme being capable of trans-splicing an RNA sequence into a target RNA sequence in vitro or in vivo, said ribozyme comprising sequences complementary to said target RNA sequence. 2. A group I type intron polynucleotide molecule, said molecule comprising a sequence encoding a trans-splicing ribozyme, the sequence of said ribozyme comprising a fusion RNA, such fusion RNA providing (1) a first RNA sequence, said first RNA sequence being sufficient for targeting said ribozyme to hybridize to a target RNA, and (2) a second RNA sequence, said second RNA sequence being capable of being transferred colinearly into a target RNA as a result of the trans-splicing activity of said ribozyme. 3. The polynucleotide molecule of claim 2, wherein said second RNA sequence comprises a sequence that encodes a peptide toxic to a host cell. 4. The polynucleotide molecule of claim 3, wherein said peptide is the DTA peptide. 5. The polynucleotide molecule of claim 4, wherein said DTA peptide is a mutant DTA peptide sequence, a) said mutant DTA peptide sequence not being expressed in the absence of trans-splicing, b) said mutant DTA peptide sequence being one where a liberated 3'-exon sequence does not give rise to a toxic translation product, c) said mutant DTA peptide sequence being encoded by that part of the ribozyme that is trans-spliced into a desired target in the host and d) wherein conditional expression of said ribozyme and said mutant DTA peptide sequence in a host cell results in death of said cell. 6. The polynucleotide molecule of claim 5, wherein said mutant peptide sequence comprises amino acids encoded by SEQ ID No. 39. 7. The polynucleotide molecule of claim 5, wherein said mutant peptide sequence comprises amino acids encoded by SEQ ID. No. 40. 8. The polynucleotide molecule of any one of claims 1-7, wherein said molecule is RNA. 9. The polynucleotide molecule of any one of claims 1-7, wherein said molecule is DNA. 10. A polynucleotide molecule comprising a ribozyme expression cassette, said cassette being capable of being stably inserted into the genome of a host, and said cassette comprising the sequence of a promoter capable of functioning in such host, operably-linked to the coding sequence of the polynucleotide of any one of claims 1-7. 11. A host cell comprising the polynucleotide molecule of claim 10. 12. The host cell of claim 11, wherein said host cell is a viral cell. 13. The host cell of claim 11, wherein said host cell is a prokaryotic cell. 14. The host cell of claim 11, wherein said host cell is a eukaryotic cell. 15. The host cell of claim 14, wherein said eukaryotic cell is a plant cell. 16. The host cell of claim 14, wherein said eukaryotic cell is an animal cell. 17. The host cell of claim 16, wherein said animal is a mammal. 18. The host cell of claim 17, wherein said animal is human. 19. A method for in vitro trans-splicing, such method comprising the steps of: (1) providing the polynucleotide molecule of any one of claims 1-7 in a trans-splicing reaction mixture, said polynucleotide comprising a sequence capable of hybridizing with a second polynucleotide; (2) providing said second polynucleotide to such a reaction mixture; (3) providing conditions that allow said polynucleotide to express said catalytic activity, and (4) catalyzing the trans-splicing of said second polynucleotide under said conditions. 20. A method for in vivo trans-splicing, said method comprising the steps of: (1) providing a polynucleotide of claim 8 to a host cell; (2) expressing said ribozyme encoded by said molecule in said host cell; (3) expressing a substrate of said ribozyme in said host cell; and (4) catalyzing the trans-splicing of said ribozyme with such substrate in said host cell. 21. A method for inactivating the activity of a target RNA, said method comprising: (1) providing the polynucleotide of any one of claims 1-7 to a trans-splicing reaction mixture, said ribozyme possessing catalytic activity against a target RNA, said catalytic activity resulting in the inactivation of the functioning of said target RNA; (2) providing said target RNA to said mixture; and (3) providing conditions that allow said polynucleotide to express said catalytic activity. 22. A method for providing a desired genetic sequence to a host cell in vivo, said method comprising: (1) providing the polynucleotide of claim 8 to said host cell, said polynucleotide possessing catalytic activity against a target RNA in said host cell, said ribozyme being capable of trans-splicing said desired genetic sequence; (2) providing said target RNA in said host cell; and (3) providing conditions that allow said ribozyme to trans-splice said desired genetic sequence into the sequence of said target RNA. 23. A method for engineering male or female sterility in a plant, said method comprising providing the polynucleotide of claim 8 to a germ cell of said species, said ribozyme being targeted to an RNA that, when expressed as a protein, is necessary for the fertility of said plant. 24. A method of conferring a desired genetic trait in a plant, said method comprising providing a germ cell of said plant with the polynucleotide of claim 8, said ribozyme encoding a trans-splicing sequence capable of conferring said desired genetic trait in said plant. 25. A method for immunizing plants against a plant pathogen, said method comprising the transforming plant cells with the polynucleotide of claim 8, wherein said polynucleotide encodes a trans-splicing sequence capable of providing immunity to said pathogen to said plant. 26. The method of claim 25, wherein said pathogen is cucumber mosaic virus. 27. A method for construction of a group I Intron pro-ribozyme, wherein said method comprises disruption of helix P8. 28. The method of claim 27, wherein said disruption is caused by P8-anti-sense base-pairing. 29. The polynucleotide molecule of any one of claims 1-7 wherein said ribozyme is a pro-ribozyme. 30. The polynucleotide molecule of claim 8 wherein said ribozyme is a pro-ribozyme. 31. The polynucleotide molecule of claim 9 wherein said ribozyme is a pro-ribozyme. 32. The polynucleotide molecule of claim 10 wherein said ribozyme is a pro-ribozyme. 33. The host cell of claim 11, wherein said ribozyme is a pro-ribozyme. 34. The method of claim 19, wherein said ribozyme is a pro-ribozyme. 35. The method of claim 20, wherein said ribozyme is a pro-ribozyme. 36. The method of claim 21, wherein said ribozyme is a pro-ribozyme. 37. The method of claim 22, wherein said ribozyme is a pro-ribozyme. 38. The method of claim 23, wherein said ribozyme is a pro-ribozyme. 39. The method of claim 24, wherein said ribozyme is a pro-ribozyme. 40. The method of claim 25, wherein said ribozyme is a pro-ribozyme.

Details for Patent 5,874,414

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-02-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-02-23
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-02-23